C34
Conditions
Interventions
Group 1: Patients receiving FDG-PET / CT for primary lung carcinoma staging (ICD10: C34) in clinical routine
to be collected:
1) quantitative parameters from the FDG-PET / CT
Standardized Uptake Values ??(SUV) of the respective lymph nodes, as well as of non-affected reference organs (e.g., the liver)
2) Histology: quantitative (malign yes / no)
qualitative (SCLC
NSCLC [subgroups])
Other data, e.g. Laboratory parameters, are not primarily part of the study. Follow-up is performed within the clinical routine for 12 months
Sponsors
Universitätsklinikum Magdeburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: FDG-PET/CT for primary staging of pulmonary cancer, informed consent, age > 18 years, sufficient histological information
Exclusion criteria
Exclusion criteria: non-existence of informed consent, withdrawal of informed consent, missing histology, pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Definition of quantitative parameters to distinguish benign vs. Malignant glucose changes in mediastinal and hilary lymph nodes The reference standard is histology. On the basis of this an optimal separation value (malignant vs. benign) is to be determined | — |
Secondary
| Measure | Time frame |
|---|---|
| definition of quantitative parameters for predicting outcome after systemic therapy (if conducted) | — |
Countries
Germany
Contacts
Public ContactAnja;Philipp Zinke;Genseke
Universitätsklinikum Magdeburg A.ö.R.Klinik für Radiologie und Nuklearmedizin;Universitätsklinikum Magdeburg A.ö.R.Klinik für Radiologie und NuklearmedizinAbteilung für Nuklearmedizin
Outcome results
None listed